Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
Ardelyx (NASDAQ:ARDX), a biopharmaceutical company focused on developing first-in-class medicines, has scheduled its second quarter 2025 financial results conference call for August 4, 2025, at 4:30 p.m. Eastern Time.
The company will discuss Q2 2025 financial performance and provide business updates. Investors can join via phone at (877) 346-6112 (domestic) or (848) 280-6350 (international). A live webcast will be available on the Investors section of www.ardelyx.com and archived for 30 days after the call.
Ardelyx (NASDAQ:ARDX), un'azienda biofarmaceutica specializzata nello sviluppo di farmaci innovativi, ha programmato la conferenza telefonica per la presentazione dei risultati finanziari del secondo trimestre 2025 per il 4 agosto 2025 alle 16:30 ora orientale.
Durante la chiamata, la società discuterà le performance finanziarie del Q2 2025 e fornirà aggiornamenti aziendali. Gli investitori potranno partecipare telefonicamente chiamando il numero (877) 346-6112 (nazionale) o (848) 280-6350 (internazionale). Una diretta streaming sarà disponibile nella sezione Investitori di www.ardelyx.com e resterà accessibile per 30 giorni dopo la chiamata.
Ardelyx (NASDAQ:ARDX), una empresa biofarmacéutica enfocada en desarrollar medicamentos innovadores, ha programado su llamada de conferencia para los resultados financieros del segundo trimestre de 2025 para el 4 de agosto de 2025 a las 4:30 p.m. hora del Este.
La compañía discutirá el desempeño financiero del Q2 2025 y proporcionará actualizaciones comerciales. Los inversionistas pueden unirse por teléfono llamando al (877) 346-6112 (nacional) o al (848) 280-6350 (internacional). Una transmisión en vivo estará disponible en la sección de Inversionistas de www.ardelyx.com y se archivará durante 30 días después de la llamada.
Ardelyx (NASDAQ:ARDX)는 혁신적인 신약 개발에 주력하는 바이오제약 회사로, 2025년 2분기 실적 발표 컨퍼런스 콜을 2025년 8월 4일 오후 4시 30분(동부 시간)에 예정했습니다.
회사는 2025년 2분기 재무 성과와 사업 현황을 논의할 예정입니다. 투자자들은 국내 전화 (877) 346-6112 또는 국제 전화 (848) 280-6350으로 참여할 수 있습니다. 라이브 웹캐스트는 www.ardelyx.com 투자자 섹션에서 제공되며, 콜 종료 후 30일간 아카이브됩니다.
Ardelyx (NASDAQ:ARDX), une société biopharmaceutique spécialisée dans le développement de médicaments innovants, a programmé sa conférence téléphonique pour les résultats financiers du deuxième trimestre 2025 le 4 août 2025 à 16h30, heure de l'Est.
La société discutera de la performance financière du T2 2025 et fournira des mises à jour commerciales. Les investisseurs peuvent participer par téléphone au (877) 346-6112 (domestique) ou au (848) 280-6350 (international). Une diffusion en direct sera disponible dans la section Investisseurs de www.ardelyx.com et archivée pendant 30 jours après l'appel.
Ardelyx (NASDAQ:ARDX), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung bahnbrechender Medikamente spezialisiert hat, hat seine Telefonkonferenz zu den Finanzergebnissen des zweiten Quartals 2025 für den 4. August 2025 um 16:30 Uhr Eastern Time angesetzt.
Das Unternehmen wird die finanzielle Performance des 2. Quartals 2025 besprechen und geschäftliche Updates geben. Investoren können telefonisch unter (877) 346-6112 (national) oder (848) 280-6350 (international) teilnehmen. Ein Live-Webcast ist im Investor-Bereich von www.ardelyx.com verfügbar und wird 30 Tage nach dem Anruf archiviert.
- None.
- None.
Conference call scheduled for 4:30 p.m. Eastern Time
WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Monday, August 4, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2025.
To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
When will Ardelyx (ARDX) report Q2 2025 earnings?
How can investors access Ardelyx's Q2 2025 earnings call?
Where can I find the replay of Ardelyx's Q2 2025 earnings webcast?
What topics will be covered in Ardelyx's Q2 2025 earnings call?
